Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection

C M Chu, Y F Liaw

Abstract

Hepatocyte expression of pre-S1 and pre-S2 in relation to hepatitis B virus replication (hepatitis B virus-DNA in serum and HBcAg in the liver), histological activity and hepatitis delta virus superinfection was studied by indirect immunofluorescence on frozen sections of liver specimens from 68 patients with chronic hepatitis B virus infection. All 44 patients with chronic type B hepatitis had pre-S1 and pre-S2 display in the liver. The distribution of pre-S1 in the liver was membranous in one, mixed membranous and cytoplasmic in 12, and cytoplasmic in 31. The distribution of pre-S2 was membranous in one, mixed membranous and cytoplasmic in 26, and cytoplasmic in 17. Membranous expression of pre-S1 was significantly more prevalent in patients with active hepatitis B virus replication than in those without (13/28 vs 0/16, p<0.001), regardless of the histological activity, as was membranous expression of pre-S2 (27/28 vs 0/16, p<0.001). In contrast, a significantly higher extent of cytoplasmic expression of pre-S1 and pre-S2 was noted in patients without active hepatitis B virus replication than in those with. Of 24 patients with chronic type D hepatitis virus, eight had active hepatitis B virus replication, and the other 16 did not. The distribution and quantitative expression of pre-S1 and pre-S2 in the liver in these patients also correlated significantly with the status of hepatitis B virus replication and, moreover, showed little or no difference from those without hepatitis delta virus infection. In conclusion, all patients with chronic type B hepatitis had synthesis and display of pre-S1 and pre-S2 in the liver. The distribution and quantitative expression of pre-S1 and pre-S2, however, were closely related to the status of hepatitis B virus replication, but not to the histological activity. Hepatocyte expression of pre-S1 and pre-S2 in chronic type D hepatitis also correlated significantly with status of hepatitis B virus replication, and was not modulated by concurrent hepatitis delta virus infection.

(Gut 1992; 33: 1544–1548)

The three envelope antigens of hepatitis B virus are now well characterised: the major protein (HBsAg) with 226 amino acids encoded by the S gene, the middle protein (pre-S2) containing HBsAg and additional 55 amino acids encoded by the pre-S2 region, and the large protein (pre-S1) encoded by entire S open reading frame, including the pre-S1 region, pre-S2 region and S gene.12 Both pre-S1 and pre-S2 proteins are expressed on the surface of HBsAg particles and may be essential components of complete virions and HBsAg filaments.14 It has also been postulated that the attachment of hepatitis B virus to hepatocytes is mediated by a receptor like function of pre-S proteins.15 Pre-S1 and pre-S2 proteins are detectable in the serum of patients with acute and chronic hepatitis B virus infection when there is high levels of viral replication, and the clearance of these antigens from serum usually correlates with the prognosis of hepatitis B virus infection.16–19

Monoclonal antibodies against pre-S proteins have recently become available for tissue staining. Intrahepatic expression of pre-S1 and pre-S2 proteins has been studied in patients with chronic hepatitis B virus infection, but the results still remain controversial.20,21 Studies of the molecular biology of hepatitis B virus have shown that the expression of HBsAg and pre-S2 protein is controlled by the same transcriptional promoter, whereas the expression of pre-S1 protein may be regulated independently by a second, usually less active, promoter.22 In addition, there is a complex interaction between HBsAg/pre-S2 and pre-S1 that can lead to the cosecretion or the inhibition of secretion of these antigens, depending on the relative concentrations of HBsAg/pre-S2 and pre-S1.23,24 It seems that, in evaluating the significance of pre-S protein display in liver in chronic hepatitis B virus infection, special emphasis should be made on their topographical (cytoplasmic or membranous) distribution as well as the quantitative expression, as suggested in the study of intrahepatic expression of HBsAg and HBcAg in chronic type B hepatitis.25 Furthermore, it has long been suggested that there is an inhibitory effect on hepatitis B virus replication by hepatitis

---

**TABLE 1 Clinical and laboratory data of patients studied**

<table>
<thead>
<tr>
<th>Category</th>
<th>Cases (n)</th>
<th>Age* (yr)</th>
<th>Sex (M:F)</th>
<th>AST (IU/l)* (n&lt;40)</th>
<th>ALT (IU/l)* (n&lt;40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without HDV superinfection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg positive MHC or CPH</td>
<td>8</td>
<td>25 (6)</td>
<td>6.2</td>
<td>44 (10)</td>
<td>50 (10)</td>
</tr>
<tr>
<td>Anti-HBe positive CAH</td>
<td>16</td>
<td>28 (8)</td>
<td>14.2</td>
<td>100 (46)</td>
<td>212 (88)</td>
</tr>
<tr>
<td>Anti-HBe positive MHC</td>
<td>10</td>
<td>33 (3)</td>
<td>10.0</td>
<td>94 (45)</td>
<td>196 (92)</td>
</tr>
<tr>
<td>With HDV superinfection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg positive CAH</td>
<td>12</td>
<td>29 (6)</td>
<td>12.0</td>
<td>92 (42)</td>
<td>191 (80)</td>
</tr>
<tr>
<td>Anti-HBe positive CAH</td>
<td>12</td>
<td>34 (7)</td>
<td>12.0</td>
<td>98 (50)</td>
<td>200 (92)</td>
</tr>
</tbody>
</table>

HDV: hepatitis delta virus; HBsAg: hepatitis e antigen; anti-HBe: antibody to HBsAg; MHC: minimal histologic change; CPH: chronic persistent hepatitis; CAH: chronic active hepatitis.

*Data are mean (SD).
delta virus in chronic hepatitis B virus infection, but it remains unclear whether hepatitis delta virus might interfere with the expression of hepatitis B virus envelope antigens in the liver or not.

In the present study, intrahepatic expression of pre-S1 and pre-S2 antigens was studied in patients with chronic type B hepatitis, and the results were correlated with the status of hepatitis B virus replication, histological activity, and hepatitis delta virus superinfection.

Methods

Patients

The study consisted of 68 patients with chronic hepatitis B virus infection. All had been HBsAg positive for more than six months and had histologic features of chronic hepatitis. Forty-four patients were chronic type B hepatitis without hepatitis delta virus superinfection, and the remainder 24 patients were chronic HBsAg carriers with hepatitis delta virus superinfection. Of the latter, all were positive for antibody against hepatitis delta virus (anti-HDV) and had hepatitis delta virus antigen (HDAG) detectable in the liver. None admitted intravenous drug abuse, nor had received antiviral or immunosuppressive treatment. The histologic diagnosis of chronic hepatitis was made according to the standard criteria. The clinical and laboratory data of the patients studied are listed in Table I.

Laboratory Methods

Serum aspartate aminotransferase and alanine aminotransferase were measured by sequential multiple autoanalysers. HBsAg, HBeAg, anti-HBe and anti-hepatitis delta virus were assayed using commercially available radioimmunoassay kits (Austria-II, HBeAg-RIA, and anti-delta, Abbott Laboratories, Chicago, Illinois, USA). Serum hepatitis B virus-DNA was assayed by spot hybridisation with 32P-labelled cloned hepatitis B virus-DNA, as reported previously.

Detection of Vital Antigens in the Liver

Liver specimens were obtained by percutaneous needle biopsy with a Menghini needle. Fragments of specimens were snap-frozen in liquid nitrogen cooled isopentane and stored at −70°C until use. Samples of the same biopsy specimens were also fixed in 10% formaldehyde and embedded in paraffin wax for routine histologic diagnosis. Cryostat sections of 5 µm were dried overnight at room temperature and fixed in carbon tetrachloride at 4°C for 10 minutes, followed by extensive washing with phosphate buffered saline (pH 7.2) before staining. HBsAg was detected by indirect immunofluorescence using mouse monoclonal antibody against the ‘a’ epitope of HBsAg (Chemicon, Temecula, CA, USA). HBeAg was detected by indirect immunofluorescence using rabbit anti-HBc (Dako Corporation, Santa Barbara, CA, USA), and HDAG was detected by indirect immunofluorescence using fluorescein isothiocyanate (FITC) labelled anti-hepatitis delta virus, kindly supplied by Dr Rizzetto, as previously reported. Pre-S1 and pre-S2 were detected by indirect immunofluorescence using mouse monoclonal antibodies against pre-S1 and pre-S2, respectively, followed by FITC-conjugated rabbit anti-mouse immunoglobulin G (Jackson Immuno Research Laboratories, West Grove, Pennsylvania, USA). Monoclonal anti-pre-S1 and anti-pre-S2, which were produced by cell line T0606 and 5520, respectively, were obtained from Institute of Immunology, Tokyo, Japan. As a control, sections were incubated with phosphate buffered saline instead of the primary monoclonal antibodies in the first step. In addition, sections of liver tissues from patients without serological markers of hepatitis B virus infection were stained using the identical techniques as negative controls. Only if the control preparations were negative was the staining considered positive. The expression of pre-S1 or pre-S2 in the liver was semiquantitatively scored according to the proportion of positive cells on a 0 to 4+ scale corresponding to positivity in 0%, 1-10%, 11-25%, 26-50%, and >50% of hepatocytes examined.

Statistical Analysis

The significance of difference between two proportions was assayed using χ² test with Yates’ correction. The difference in the number of hepatocytes positive for pre-S1 or pre-S2 between two groups of patients was compared using Wilcoxon’s rank-sum test.

Results

All of the 68 patients, with or without hepatitis delta virus infection, had the three hepatitis B virus envelope proteins detectable in the liver, on the plasma membrane and/or in the cytoplasm. The expression of the hepatitis B virus envelope proteins on the plasma membrane was usually diffuse, while that in the cytoplasm was either focal or in clusters. Figures 1 and 2 illustrate the representative findings of the expression of pre-S2 in the liver. The distribution and quantitative expression of pre-S2 were essentially the same as those of HBsAg. The expression of pre-S1 was solely membranous in one, mixed membranous
and cytoplasmic in 16, and exclusively cytoplasmic in 51. The expression of pre-S2 was solely membranous in one, mixed membranous and cytoplasmic in 32, and exclusively cytoplasmic in 35. Membranous expression of pre-S2 is significantly more frequent than that of pre-S1 (48.5% or 33/68 ± 25% or 17/68, p<0.01).

Of 44 patients with chronic type B hepatitis without hepatitis delta virus infection, 28 were positive for hepatitis B virus-DNA in serum and HBCAg in the liver, and the remainder 16 were negative for both. The distribution of pre-S1 and pre-S2 in chronic type B hepatitis without hepatitis delta virus infection, in relation to the status of hepatitis B virus replication and histological activity, is listed in Table II. Diffuse membranous expression of pre-S2, usually in combination with focal cytoplasmic expression, was found in 27 (96-4%) of 28 patients with active hepatitis B virus replication, irrespective of serum HBeAg or histological activity, but in none of 16 patients without active hepatitis B virus replication (p<0.001). Membranous expression of pre-S1 also correlated significantly with the status of hepatitis B virus replication. Cytoplasmic expression of pre-S1 and pre-S2 was noted in 43 and 43 patients, respectively. Semiquantitative analysis revealed that the degrees of cytoplasmic expression of pre-S1 as well as pre-S2 were significantly higher in patients without active hepatitis B virus replication than in those with (Table III).

Of the 24 patients with chronic type D hepatitis, eight were positive for hepatitis B virus-DNA in serum and HBCAg in the liver, and the remainder 16 were negative for both. Table IV shows the distribution of pre-S1 and pre-S2 in the liver in chronic hepatitis delta virus infection. Membranous expression of pre-S1 and pre-S2 correlated significantly with active hepatitis B virus replication. Moreover, a significantly higher degree of cytoplasmic expression of pre-S1 and pre-S2 was noted in patients without active hepatitis B virus replication than in those with (Table V). The distribution and quantitative expression of pre-S1 and pre-S2 in the liver in patients with chronic type D hepatitis was comparable to those without hepatitis delta virus infection.

**Discussion**

The present results showed that all patients with chronic hepatitis B virus infection had pre-S1 or pre-S2 detectable in the liver, irrespective of the status of hepatitis B virus replication or histological activity. These findings are in keeping with the previous observations,1 12 13 17 19, 20 but are in contrast with the suggestion by other groups that the expression of pre-S1 or pre-S2 in liver varied with the status of hepatitis B virus replication.14 16 17 This discrepancy may be because of the difference in the choice of antisera, tissue manipulation or staining protocols. Furthermore, the expression of HBsAg in liver was essentially identical to that of pre-S2 but not that of pre-S1, in keeping with the suggestion that transcription of mRNAs for HBsAg and pre-S2 is controlled by the same promotor, and that for pre-S1 is controlled independently by a second

---

**Figure 2:** Indirect immunofluorescence staining of pre-S2 on frozen section of the liver from an anti-HBe-positive patient with minimal histological change, showing widespread expression of pre-S2 in the cytoplasm.

**Table II** Intrahepatic expression of pre-S1 and pre-S2 in chronic type B hepatitis

<table>
<thead>
<tr>
<th>Category</th>
<th>Pre-S2</th>
<th>Pre-S1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M/M+C/C</td>
<td>Cases with membranous pre-S2 (%)</td>
</tr>
<tr>
<td>With active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBeAg positive MHC or CPH (n=8)</td>
<td>0/7/1</td>
<td>87.5</td>
</tr>
<tr>
<td>HBeAg positive CAH (n=16)</td>
<td>1/15/0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-HBe positive CAH (n=4)</td>
<td>0/4/0</td>
<td>100.0</td>
</tr>
<tr>
<td>Subtotal (n=28)</td>
<td>1/2/6</td>
<td>96.4*</td>
</tr>
<tr>
<td>Without active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-HBe positive CAH (n=6)</td>
<td>0/0/0</td>
<td>0.0</td>
</tr>
<tr>
<td>Anti-HBe positive MHC (n=10)</td>
<td>0/0/0</td>
<td>0.0</td>
</tr>
<tr>
<td>Subtotal (n=16)</td>
<td>0/0/16</td>
<td>0*</td>
</tr>
</tbody>
</table>

**Table III** Semiquantitative expression of pre-S1 and pre-S2 in hepatocyte cytoplasm in chronic type B hepatitis

<table>
<thead>
<tr>
<th>Category</th>
<th>Pre-S2</th>
<th>Pre-S1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>With active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBeAg positive MHC or CPH (n=8)</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>HBeAg positive CAH (n=16)</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Anti-HBe positive CAH (n=4)</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Subtotal (n=28)</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Without active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-HBe positive CAH (n=6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anti-HBe positive MHC (n=10)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Subtotal (n=16)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

For abbreviations, see Tables I and II. Scales of 0 to 4+ corresponding to positivity in 0%, 1-10%, 11-25%, 26-50%, >50% of total hepatocytes examined.

**Table IV** Intrahepatic expression of pre-S1 and pre-S2 in chronic type D hepatitis

<table>
<thead>
<tr>
<th>Category</th>
<th>Pre-S2</th>
<th>Pre-S1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M+C/C</td>
<td>Cases with membranous pre-S2 (%)</td>
</tr>
<tr>
<td>With active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBeAg positive CAH (n=8)</td>
<td>6/2</td>
<td>75.0*</td>
</tr>
<tr>
<td>Without active HBV replication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBeAg positive CAH (n=4)</td>
<td>0/4</td>
<td>0</td>
</tr>
<tr>
<td>Anti-HBe positive CAH (n=12)</td>
<td>0/12</td>
<td>0</td>
</tr>
<tr>
<td>Subtotal (n=16)</td>
<td>0/16</td>
<td>0*</td>
</tr>
</tbody>
</table>

For abbreviations, see Tables I and II.

*p<0.001, *p<0.01 by χ² test with Yates' correction.
promotor.\textsuperscript{21,22} This observation also implies that there is control at the level of translation of pre-S2\textsuperscript{+} HBsAg.

Perhaps the more important finding of the present study is that the distribution and quantitative expression of pre-S1 and pre-S2 in the liver differed remarkably with the status of hepatitis B virus replication. During active replication of hepatitis B virus, nearly all patients had pre-S2 expression on the plasma membrane, regardless of serum HBsAg or liver inflammatory activity. Similarly, membranous expression of pre-S1 also correlated significantly with active hepatitis B virus replication (Table II). Previous studies by others have shown a close association between high levels of pre-S1 or pre-S2 in serum with hepatitis B virus-DNA in serum,\textsuperscript{7-11} in keeping with the observation that pre-S1 and pre-S2 are the essential components of complete virion.\textsuperscript{14} Taken together, it seems that, membranous expression of pre-S1 or pre-S2 in the liver is closely related to its presence in serum, and thus might reflect the secretion of the hepatitis B virus particles containing pre-S peptides by liver into the circulation, suggesting a pathway through membranous system in assembly or secretion of hepatitis B virus particles. On the contrary, in patients without active hepatitis B virus replication, there is little or no membranous expression of pre-S1 or pre-S2, and, moreover, cytoplasmic expression of pre-S peptides increased remarkably compared with those with active hepatitis B virus replication (Table III). These findings might suggest that in the non-replicative phase of chronic hepatitis B virus infection, pre-S1 or pre-S2 is non-secretable, and thus will be retained within the cytoplasm of the hepatocytes. The reason for the relatively less prevalence of pre-S1 than of pre-S2 on the liver cell membrane during active hepatitis B virus replication, as shown in Table II, is not clear. A similar finding, however, has been reported recently by Suzuki et al.\textsuperscript{18} It remains possible that monoclonal antibody against pre-S1 used in the present study has less affinity to the plasma membrane of hepatocyte than that against pre-S2.

The mechanism responsible for secretion or intracellular retention of pre-S peptides in chronic hepatitis B virus infection is uncertain. Studies in cultured cells have suggested that the cosecretion or the inhibition of secretion of HBsAg/pre-S2 and pre-S1 might depend on their relative concentrations.\textsuperscript{23,24} On the other hand, it has been suggested that, unlike HBsAg, the pre-S peptides do not undergo the spontaneous budding process; rather the initiation of budding might be triggered by interaction with the nucleocapsid or matrix components of the virus.\textsuperscript{24-26} It seems more likely that, in the absence of active hepatitis B virus replication and intracellular nucleocapsid protein (HBcAg), surplus pre-S peptides cannot migrate to the plasma membrane as part of new assembling particles and thus will accumulate in the cytoplasm.

Several studies have shown a close association between liver inflammatory activities and membrane associated pre-S1 or pre-S2 in chronic hepatitis B virus infection, suggesting that membranous pre-S1 or pre-S2 might be a possible target antigen in T-cell mediated lysis of hepatocytes.\textsuperscript{24,64} Studies of the in vitro microcytotoxicity assays, however, have suggested hepatitis B virus capsid protein, rather than envelope protein, as a target viral antigen.\textsuperscript{6} The present results revealed that membranous expression of pre-S1 or pre-S2 was found in patients with hepatitis B virus-DNA in serum or HBsAg in liver, regardless of the histological activity, suggesting that membranous expression of pre-S1 or pre-S2 is closely related to active replication of hepatitis B virus, rather than the extent of liver inflammatory activity.

With regard to the interference of pre-S1 or pre-S2 expression in the liver in chronic hepatitis delta virus infection, a recent study by Hadziyannis et al\textsuperscript{20} has suggested that intrahepatic expression of pre-S peptides in chronic hepatitis delta virus infection appeared to be independent of hepatitis B virus and hepatitis delta virus replicative status. In the Hadziyannis's series, however, the majority of patients were negative for HBsAg in serum or HBsAg in the liver, and there was no quantitative data of pre-S peptide expression in the liver. The present results showed that the topographic distribution of pre-S1 and pre-S2 in the liver in HBsAg carriers with hepatitis delta virus infection correlated significantly with the status of hepatitis B virus replication (Table IV), and that, moreover, the distribution and quantitative expression of pre-S1 and pre-S2 were comparable with the hepatitis delta virus negative patients (Tables III, V). These findings suggested that in HBsAg carriers with chronic hepatitis delta virus infection the synthesis and expression of pre-S peptides in liver correlated closely with the underlying hepatitis B virus replicative status and did not appear to be modulated by the concurrent hepatitis delta virus infection.

In conclusion, the present results suggested that all patients with chronic hepatitis B virus infection had pre-S1 or pre-S2 display in the liver. The distribution and quantitative expression of pre-S peptides in the liver, however, were closely related to the status of hepatitis B virus replication, but not to the histological activity. Concurrent hepatitis delta virus superinfection did not appear to modulate the synthesis and expression of pre-S peptides in the liver.
1548 Chu, Liaw


14 Klinkert MQ, Theilmann L, Pr all E. Pre-S1 antigens and antibodies early in the course of acute hepatitis B virus infection. J Viral 1986; 56: 322-9.


70 Chu CM, Liaw YF, Sheen IS, Chen TJ. Intrahepatic expression of HBcAg and delta antigen in anti-HBe positive HBsAg carriers with acute exacerbation or chronic liver disease. J Med Viral 1990; 30: 181-6.


